Drug discontinuation: Crinecerfont Capsule
FDA lists 1 presentation as To Be Discontinued. Companies: Neurocrine Biosciences, Inc..
- Published by source
- 2026-04-28
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Neurocrine Biosciences, Inc.
- Products
- Crinecerfont Capsule
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-04-28
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1069 | new | 2026-10-22 | 46e6eb10571a…84a684 | 2a61e127dde4…80401a |
Chain head: #1076 8ad5adc30b9b…88ce20